Financial Reports

Annual Report 2015-2016


CSL delivers another strong performance with double digit growth in all plasma therapy groups. This year we secured approvals and launches for five new products, including our two novel recombinant coagulation products IDELVION® and AFSTYLA® and three differentiated influenza vaccine products. 

2016 AR Cover  








Past Annual and Half Year Reports:

2015-2016
2014-2015
2013-2014
2012-2013
2011-2012
2010-2011
2009-2010



 # Constant currency removes the impact of exchange rate movements to facilitate comparability. For further details refer to page 47 in the Directors’ Report in the 2014-15 Annual Report.

     

© 2016 CSL Limited